SMART Medical Systems Ltd., a developer and manufacturer of innovative endoscopy products, today reported positive data from a multicenter clinical study (NCT 04708951) comparing the adenoma detection rate (ADR) of its FDA-cleared G-EYE® balloon technology against ENDOCUFF VISION® (ECV) technology in patients undergoing screening or surveillance colonoscopy. Results from this randomized trial, the first head-to-head comparison of these two colonoscopy mechanical enhancement devices, showed that the ADR, particularly for advanced and large adenomas, was higher for the G-EYE® balloon than for the ECV attachment. Seth Gross, MD, Professor, Department of Medicine at NYU Grossman School of Medicine, Clinical Chief, Division of Gastroenterology and Hepatology at NYU Langone Health, and co-author on the abstract, presented the data in an oral session at ACG 2021, which is taking place October 22-27 in Las Vegas (ACG 2021, Presidential Plenary Session 1, Abstract #S233).
Trending
- Ulcerative Colitis: Next Target for CAR T-Cell Therapy? (Medpage Today)
- A Global Cascade Approach to Diagnosis and Management of Chronic Constipation (World Gastroenterology Organisation)
- Albany Gastroenterology Consultants: November 2024 Data Breach Affects Almost 58,000 Patients (The HIPAA Journal)
- World’s Top HealthTech Companies of 2025 (TIME)
- Gut Microbiome Changes Link Soft Drinks with Depression (Inside Precision Medicine)
- World’s First Fully Robotic Procedure by a Gastroenterologist Completed Using EndoQuest’s Endoluminal Surgical System in the PARADIGM Trial (GlobeNewswire)
- J&J exits Linx esophageal reflux business in some countries (MedTech Dive)
- Over half of US healthcare workers plan to switch jobs by next year, survey finds (Reuters)